Immunohistochemical profile for unknown primary adenocarcinoma

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Hashimoto, Kenji ^a   Sasajima, Yuko ^a   Ando, Masashi ^a   Yonemori, Kan ^a   Hirakawa, Akihiro ^b   Furuta, Koh ^a   Tsuda, Hitoshi ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOKERATIN 17; CYTOKERATIN 19; CYTOKERATIN 20; CYTOKERATIN 7; DOCETAXEL; ESTROGEN RECEPTOR; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; PROTEIN GCDFP 15; PROTEIN WT 1; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR PAX8; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BILIARY TRACT ADENOCARCINOMA; BIOPSY; BREAST ADENOCARCINOMA; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE MARKER; EGFR GENE; ENDOMETRIUM CARCINOMA; FEMALE; HEPATOCELLULAR ADENOCARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; RENAL CELL ADENOCARCINOMA; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR GENE; UROTHELIAL ADENOCARCINOMA; ALGORITHM; CLINICAL TRIAL; COHORT ANALYSIS; DIFFERENTIAL DIAGNOSIS; METABOLISM; METABOLOME; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; SURVIVAL;

IPS;

ADENOCARCINOMA; ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METABOLOME; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856386227     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031181     Document Type: Article

References (44)

1. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA, (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39: 1990-2005.
2. Pavlidis N, Briasoulis E, Pentheroudakis G, (2010) Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5): v228-231.
3. Pavlidis N, Fizazi K, (2005) Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 54: 243-250.
4. Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, et al. (2009) Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev 35: 570-573.
5. Yonemori K, Ando M, Yunokawa M, Hirata T, Kouno T, et al. (2009) Irinotecan plus carboplatin for patients with carcinoma of unknown primary site. Br J Cancer 100: 50-55.
6. Mukai H, Katsumata N, Ando M, Watanabe T, (2010) Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer. Am J Clin Oncol 33: 32-35.
7. Monzon FA, Lyons-Weiler M, Buturovic LJ, Rigl CT, Henner WD, et al. (2009) Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 27: 2503-2508.
8. Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, et al. (2008) Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 26: 4435-4441.
9. Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL, (2008) Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 9: 596-599.
10. Tot T, (2002) Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer 38: 758-763.
11. Tanaka S, Saito K, Ito T, Tajima K, Mogi A, et al. (2007) CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. Oncol Rep 18: 87-92.
12. Park do Y, Srivastava A, Kim GH, Mino-Kenudson M, Deshpande V, et al. (2009) CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance. Mod Pathol 23: 54-61.
13. Werling RW, Yaziji H, Bacchi CE, Gown AM, (2003) CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 27: 303-310.
14. Saqi A, Alexis D, Remotti F, Bhagat G, (2005) Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol 123: 394-404.
15. Chhieng DC, Cangiarella JF, Zakowski MF, Goswami S, Cohen JM, et al. (2001) Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer 93: 330-336.
16. Nonaka D, Chiriboga L, Soslow RA, (2008) Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol 32: 1566-1571.
17. Dupont J, Wang X, Marshall DS, Leitao M, Hedvat CV, et al. (2004) Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol 94: 449-455.
18. Ciampa A, Fanger G, Khan A, Rock KL, Xu B, (2004) Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas. Cancer 102: 368-372.
19. Chia SY, Thike AA, Cheok PY, Tan PH, (2010) Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors. Breast 19: 355-359.
20. Perry A, Parisi JE, Kurtin PJ, (1997) Metastatic adenocarcinoma to the brain: an immunohistochemical approach. Hum Pathol 28: 938-943.
21. Takeda Y, Tsuta K, Shibuki Y, Hoshino T, Tochigi N, et al. (2008) Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors. Arch Pathol Lab Med 132: 239-243.
22. Mhawech P, Uchida T, Pelte MF, (2002) Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol 33: 1136-1140.
23. Lai Y, Ye J, Chen J, Zhang L, Wasi L, et al. (2010) UPK3A: a promising novel urinary marker for the detection of bladder cancer. Urology 76: 514 e516-511.
24. Goldstein NS, (2002) Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 117: 471-477.
25. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, et al. (2005) Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 11: 3766-3772.
26. Lotan TL, Ye H, Melamed J, Wu XR, Shih Ie M, et al. (2009) Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol 33: 1037-1041.
27. Morris JPt, Wang SC, Hebrok M, (2010) KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 10: 683-695.
28. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM, (2005) Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol 29: 359-367.
29. Allred DC, Harvey JM, Berardo M, Clark GM, (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168.
30. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312-3318.
31. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
32. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106.
33. Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, et al. (2011) Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). Ann Oncol 22: 636-642.
34. Saito I, Kitagawa R, Fukuda H, Shibata T, Katsumata N, et al. (2010) A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol 40: 90-93.
35. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, et al. (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26: 1435-1442.
36. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30.
37. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, et al. (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281.
38. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Carteni G, et al. (2010) Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28: 1645-1651.
39. Centeno BA, Bloom G, Chen DT, Chen Z, Gruidl M, et al. (2010) Hybrid model integrating immunohistochemistry and expression profiling for the classification of carcinomas of unknown primary site. J Mol Diagn 12: 476-486.
40. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, et al. (2008) Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26: 4442-4448.
41. Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, et al. (2008) EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 26: 5589-5595.
42. Pentheroudakis G, Briasoulis E, Pavlidis N, (2007) Cancer of unknown primary site: missing primary or missing biology? Oncologist 12: 418-425.
43. Pentheroudakis G, Golfinopoulos V, Pavlidis N, (2007) Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 43: 2026-2036.
44. Vincent t, DeVita Jr, (1997) Samuel Hellman SAR Cancer principles and practice of oncology Philadelphia Lippincott Williams and Wilkins.